Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04882098




Registration number
NCT04882098
Ethics application status
Date submitted
10/05/2021
Date registered
11/05/2021
Date last updated
24/10/2024

Titles & IDs
Public title
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
Scientific title
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Subcutaneously Administered Guselkumab in Improving the Signs and Symptoms and Inhibiting Radiographic Progression in Participants With Active Psoriatic Arthritis
Secondary ID [1] 0 0
2020-004981-20
Secondary ID [2] 0 0
CR108957
Universal Trial Number (UTN)
Trial acronym
APEX
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Arthritis, Psoriatic 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Osteoarthritis
Inflammatory and Immune System 0 0 0 0
Rheumatoid arthritis
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Guselkumab
Treatment: Drugs - Placebo

Experimental: Group 1: Guselkumab and Placebo - Participants will receive guselkumab and placebo subcutaneously (SC) to maintain the blind. Participants who have not discontinued will be eligible to enter a long-term extension (LTE) and will receive guselkumab and placebo SC. After the study is unblinded to the investigative sites, participants will receive guselkumab and no longer be required to dose with placebo to maintain the blind.

Experimental: Group 2: Guselkumab - Participants will receive guselkumab SC. Participants who have not discontinued will be eligible to enter an LTE and will receive guselkumab SC.

Experimental: Group 3: Placebo Followed by Guselkumab - Participants will receive placebo SC and will cross over to receive SC guselkumab. Participants who have not discontinued will be eligible to enter an LTE and will receive guselkumab SC.


Treatment: Drugs: Guselkumab
Participants will receive guselkumab as SC injection.

Treatment: Drugs: Placebo
Participants will receive matching placebo as SC injection.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24
Timepoint [1] 0 0
Week 24
Secondary outcome [1] 0 0
Change From Baseline in Psoriatic Arthritis (PsA) Modified Van Der Heijde-Sharp (vdH-S) Total Score at Week 24
Timepoint [1] 0 0
Baseline and Week 24
Secondary outcome [2] 0 0
Number of Participants with Adverse Events (AEs), Serious Adverse Events (SAEs), Reasonably Related AEs, as a Measure of Safety and Tolerability
Timepoint [2] 0 0
Up to 168 weeks
Secondary outcome [3] 0 0
Number of Participants with AEs leading to Discontinuation of Study Intervention
Timepoint [3] 0 0
Up to 168 weeks
Secondary outcome [4] 0 0
Number of Participants with Infections
Timepoint [4] 0 0
Up to 168 weeks
Secondary outcome [5] 0 0
Number of Participants with AEs Temporally Associated With an Injection-site Reactions
Timepoint [5] 0 0
Up to 168 weeks
Secondary outcome [6] 0 0
Number of Participants With Change from Baseline in Clinical Laboratory Abnormalities
Timepoint [6] 0 0
Baseline, up to 168 weeks
Secondary outcome [7] 0 0
Number of Participants with Maximum Common Terminology Criteria for Adverse Events (CTCAE) toxicity grade Laboratory Values
Timepoint [7] 0 0
Up to 168 weeks
Secondary outcome [8] 0 0
Serum Guselkumab Concentration
Timepoint [8] 0 0
Up to 168 weeks
Secondary outcome [9] 0 0
Number of Participants with Anti-guselkumab Antibodies
Timepoint [9] 0 0
Up to 168 weeks

Eligibility
Key inclusion criteria
* Have active psoriatic arthritis (PsA) despite previous non-biologic disease-modifying antirheumatic drug (DMARD), apremilast, and/or nonsteroidal anti-inflammatory drug (NSAID) therapy
* Have a diagnosis of PsA for at least 6 months before the first administration of study agent and meet Classification criteria for Psoriatic Arthritis (CASPAR) at screening
* Have active PsA as defined by: at least 3 swollen joints and 3 tender joints at screening and at baseline; and C-reactive protein (CRP) greater than or equal to (>=) 0.3 milligrams per deciliter (mg/dL) at screening from the central laboratory
* Have >= 2 joints with erosions on baseline radiographs of the hands and feet as determined by central read
* Have at least one of the following PsA subsets: distal interphalangeal joint involvement, polyarticular arthritis with absence of rheumatoid nodules, arthritis mutilans, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis
* Have active plaque psoriasis, with at least one psoriatic plaque of >= 2 centimeter (cm) diameter or nail changes consistent with psoriasis
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Has known allergies, hypersensitivity, or intolerance to study intervention or its excipients
* Has other inflammatory diseases that might confound the evaluations of benefit of guselkumab therapy, including but not limited to rheumatoid arthritis (RA), axial spondyloarthritis (AS)/non-radiographic axial spondyloarthritis (nr-axSpA), systemic lupus erythematosus, or Lyme disease
* Has previously received any biologic treatment
* Has ever received tofacitinib, baricitinib, filgotinib, peficitinib, decernotinib, upadacitinib or any other Janus kinase (JAK) inhibitor
* Has received any systemic immunosuppressants (example, azathioprine, cyclosporine, 6 thioguanine, mercaptopurine, mycophenolate mofetil, hydroxyurea, tacrolimus) within 4 weeks of the first administration of study intervention

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
17/06/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
8/12/2027
Actual
Sample size
Target
950
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
The Queen Elizabeth Hospital - Adelaide
Recruitment hospital [2] 0 0
Southern Clinical Research - Hobart
Recruitment hospital [3] 0 0
Emeritus Research - Melbourne
Recruitment hospital [4] 0 0
Eastern Health - Box Hill Hospital - Melbourne
Recruitment hospital [5] 0 0
Rheumatology Research Unit - Sunshine Coast
Recruitment postcode(s) [1] 0 0
5011 - Adelaide
Recruitment postcode(s) [2] 0 0
7000 - Hobart
Recruitment postcode(s) [3] 0 0
3124 - Melbourne
Recruitment postcode(s) [4] 0 0
3128 - Melbourne
Recruitment postcode(s) [5] 0 0
4558 - Sunshine Coast
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Maryland
Country [6] 0 0
United States of America
State/province [6] 0 0
Michigan
Country [7] 0 0
United States of America
State/province [7] 0 0
Missouri
Country [8] 0 0
United States of America
State/province [8] 0 0
Montana
Country [9] 0 0
United States of America
State/province [9] 0 0
New York
Country [10] 0 0
United States of America
State/province [10] 0 0
North Carolina
Country [11] 0 0
United States of America
State/province [11] 0 0
Ohio
Country [12] 0 0
United States of America
State/province [12] 0 0
Pennsylvania
Country [13] 0 0
United States of America
State/province [13] 0 0
Tennessee
Country [14] 0 0
United States of America
State/province [14] 0 0
Texas
Country [15] 0 0
Bosnia and Herzegovina
State/province [15] 0 0
Banja Luka
Country [16] 0 0
Bosnia and Herzegovina
State/province [16] 0 0
Gradiska
Country [17] 0 0
Bosnia and Herzegovina
State/province [17] 0 0
Mostar
Country [18] 0 0
Bosnia and Herzegovina
State/province [18] 0 0
Sarajevo
Country [19] 0 0
Bulgaria
State/province [19] 0 0
Plovdiv
Country [20] 0 0
Bulgaria
State/province [20] 0 0
Ruse
Country [21] 0 0
Bulgaria
State/province [21] 0 0
Sevlievo
Country [22] 0 0
Bulgaria
State/province [22] 0 0
Sofia
Country [23] 0 0
Canada
State/province [23] 0 0
Newfoundland and Labrador
Country [24] 0 0
Canada
State/province [24] 0 0
Ontario
Country [25] 0 0
Canada
State/province [25] 0 0
Quebec
Country [26] 0 0
China
State/province [26] 0 0
Baoding
Country [27] 0 0
China
State/province [27] 0 0
Baotou
Country [28] 0 0
China
State/province [28] 0 0
Beijing
Country [29] 0 0
China
State/province [29] 0 0
Bengbu
Country [30] 0 0
China
State/province [30] 0 0
Changchun
Country [31] 0 0
China
State/province [31] 0 0
Changzhou
Country [32] 0 0
China
State/province [32] 0 0
Chengdu
Country [33] 0 0
China
State/province [33] 0 0
Chongqing
Country [34] 0 0
China
State/province [34] 0 0
Guangzhou
Country [35] 0 0
China
State/province [35] 0 0
Guiyang
Country [36] 0 0
China
State/province [36] 0 0
Hangzhou
Country [37] 0 0
China
State/province [37] 0 0
Linyi
Country [38] 0 0
China
State/province [38] 0 0
Nanchang
Country [39] 0 0
China
State/province [39] 0 0
Nanjing
Country [40] 0 0
China
State/province [40] 0 0
Pingxiang
Country [41] 0 0
China
State/province [41] 0 0
Shanghai
Country [42] 0 0
China
State/province [42] 0 0
Shenyang
Country [43] 0 0
China
State/province [43] 0 0
Taiyuan
Country [44] 0 0
China
State/province [44] 0 0
Zhengzhou
Country [45] 0 0
Croatia
State/province [45] 0 0
Osijek
Country [46] 0 0
Croatia
State/province [46] 0 0
Rijeka
Country [47] 0 0
Croatia
State/province [47] 0 0
Split
Country [48] 0 0
Croatia
State/province [48] 0 0
Zagreb
Country [49] 0 0
Czechia
State/province [49] 0 0
Brno Zidenice
Country [50] 0 0
Czechia
State/province [50] 0 0
Brno
Country [51] 0 0
Czechia
State/province [51] 0 0
Hlucin
Country [52] 0 0
Czechia
State/province [52] 0 0
Ostrava
Country [53] 0 0
Czechia
State/province [53] 0 0
Pardubice
Country [54] 0 0
Czechia
State/province [54] 0 0
Prague
Country [55] 0 0
Czechia
State/province [55] 0 0
Praha 4
Country [56] 0 0
Czechia
State/province [56] 0 0
Praha
Country [57] 0 0
Czechia
State/province [57] 0 0
Uherske Hradiste
Country [58] 0 0
Czechia
State/province [58] 0 0
Zlin
Country [59] 0 0
Estonia
State/province [59] 0 0
Tallinn
Country [60] 0 0
Estonia
State/province [60] 0 0
Tartu
Country [61] 0 0
Georgia
State/province [61] 0 0
Batumi
Country [62] 0 0
Georgia
State/province [62] 0 0
Kutaisi
Country [63] 0 0
Georgia
State/province [63] 0 0
Tbilisi
Country [64] 0 0
Germany
State/province [64] 0 0
Berlin
Country [65] 0 0
Germany
State/province [65] 0 0
Hamburg
Country [66] 0 0
Germany
State/province [66] 0 0
Herne
Country [67] 0 0
Germany
State/province [67] 0 0
Magdeburg
Country [68] 0 0
Germany
State/province [68] 0 0
Mainz
Country [69] 0 0
Germany
State/province [69] 0 0
Ratingen
Country [70] 0 0
Greece
State/province [70] 0 0
Athens
Country [71] 0 0
Greece
State/province [71] 0 0
Larissa
Country [72] 0 0
Greece
State/province [72] 0 0
Xanthi
Country [73] 0 0
Hungary
State/province [73] 0 0
Budapest
Country [74] 0 0
Hungary
State/province [74] 0 0
Debrecen
Country [75] 0 0
Hungary
State/province [75] 0 0
Gyula
Country [76] 0 0
Hungary
State/province [76] 0 0
Kistarcsa
Country [77] 0 0
Hungary
State/province [77] 0 0
Szeged
Country [78] 0 0
Hungary
State/province [78] 0 0
Szentes
Country [79] 0 0
Hungary
State/province [79] 0 0
Szolnok
Country [80] 0 0
Hungary
State/province [80] 0 0
Zalaegerszeg
Country [81] 0 0
Israel
State/province [81] 0 0
Ashkelon
Country [82] 0 0
Israel
State/province [82] 0 0
Haifa
Country [83] 0 0
Israel
State/province [83] 0 0
Kfar Saba
Country [84] 0 0
Israel
State/province [84] 0 0
Petah Tikva
Country [85] 0 0
Israel
State/province [85] 0 0
Ramat Gan
Country [86] 0 0
Israel
State/province [86] 0 0
Tel Aviv
Country [87] 0 0
Italy
State/province [87] 0 0
Catania
Country [88] 0 0
Italy
State/province [88] 0 0
Milano
Country [89] 0 0
Italy
State/province [89] 0 0
Napoli
Country [90] 0 0
Italy
State/province [90] 0 0
Palermo
Country [91] 0 0
Italy
State/province [91] 0 0
Roma
Country [92] 0 0
Italy
State/province [92] 0 0
Rome
Country [93] 0 0
Italy
State/province [93] 0 0
Torino
Country [94] 0 0
Italy
State/province [94] 0 0
Verona
Country [95] 0 0
Korea, Republic of
State/province [95] 0 0
Cheonan-si
Country [96] 0 0
Korea, Republic of
State/province [96] 0 0
Gwangju-si
Country [97] 0 0
Korea, Republic of
State/province [97] 0 0
Seoul
Country [98] 0 0
Korea, Republic of
State/province [98] 0 0
Suwon
Country [99] 0 0
Latvia
State/province [99] 0 0
Adazi
Country [100] 0 0
Latvia
State/province [100] 0 0
Riga
Country [101] 0 0
Lithuania
State/province [101] 0 0
Kaunas
Country [102] 0 0
Lithuania
State/province [102] 0 0
Klaipeda
Country [103] 0 0
Lithuania
State/province [103] 0 0
Siauliai
Country [104] 0 0
Lithuania
State/province [104] 0 0
Vilnius
Country [105] 0 0
Malaysia
State/province [105] 0 0
Batu Caves
Country [106] 0 0
Malaysia
State/province [106] 0 0
Ipoh
Country [107] 0 0
Malaysia
State/province [107] 0 0
Kuala Lumpur
Country [108] 0 0
Malaysia
State/province [108] 0 0
Melaka
Country [109] 0 0
Malaysia
State/province [109] 0 0
Petaling Jaya, Selangor
Country [110] 0 0
Malaysia
State/province [110] 0 0
Seremban
Country [111] 0 0
Philippines
State/province [111] 0 0
Angeles
Country [112] 0 0
Philippines
State/province [112] 0 0
Cebu
Country [113] 0 0
Philippines
State/province [113] 0 0
Dasmarinas
Country [114] 0 0
Philippines
State/province [114] 0 0
Davao City
Country [115] 0 0
Philippines
State/province [115] 0 0
Davao
Country [116] 0 0
Philippines
State/province [116] 0 0
Las Pinas
Country [117] 0 0
Philippines
State/province [117] 0 0
Manila
Country [118] 0 0
Poland
State/province [118] 0 0
Bialystok
Country [119] 0 0
Poland
State/province [119] 0 0
Bydgoszcz
Country [120] 0 0
Poland
State/province [120] 0 0
Elblag
Country [121] 0 0
Poland
State/province [121] 0 0
Gdynia
Country [122] 0 0
Poland
State/province [122] 0 0
Kraków
Country [123] 0 0
Poland
State/province [123] 0 0
Lublin
Country [124] 0 0
Poland
State/province [124] 0 0
Nadarzyn
Country [125] 0 0
Poland
State/province [125] 0 0
Nowa Sol
Country [126] 0 0
Poland
State/province [126] 0 0
Poznan
Country [127] 0 0
Poland
State/province [127] 0 0
Torun
Country [128] 0 0
Poland
State/province [128] 0 0
Warsaw
Country [129] 0 0
Poland
State/province [129] 0 0
Warszawa
Country [130] 0 0
Poland
State/province [130] 0 0
Wroclaw
Country [131] 0 0
Russian Federation
State/province [131] 0 0
Chelyabinsk
Country [132] 0 0
Russian Federation
State/province [132] 0 0
Izhevsk
Country [133] 0 0
Russian Federation
State/province [133] 0 0
Kazan
Country [134] 0 0
Russian Federation
State/province [134] 0 0
Kemerovo
Country [135] 0 0
Russian Federation
State/province [135] 0 0
Moscow
Country [136] 0 0
Russian Federation
State/province [136] 0 0
Novosibirsk
Country [137] 0 0
Russian Federation
State/province [137] 0 0
Orenburg
Country [138] 0 0
Russian Federation
State/province [138] 0 0
Petrozavodsk
Country [139] 0 0
Russian Federation
State/province [139] 0 0
Ryazan
Country [140] 0 0
Russian Federation
State/province [140] 0 0
Sankt-Petersburg.
Country [141] 0 0
Russian Federation
State/province [141] 0 0
Saratov
Country [142] 0 0
Russian Federation
State/province [142] 0 0
St. Petersburg
Country [143] 0 0
Russian Federation
State/province [143] 0 0
St.-Petersburg
Country [144] 0 0
Russian Federation
State/province [144] 0 0
Ulyanovsk
Country [145] 0 0
Russian Federation
State/province [145] 0 0
Vladimir
Country [146] 0 0
Russian Federation
State/province [146] 0 0
Yaroslavl
Country [147] 0 0
Serbia
State/province [147] 0 0
Belgrade
Country [148] 0 0
Serbia
State/province [148] 0 0
Kragujevac
Country [149] 0 0
Serbia
State/province [149] 0 0
Niska Banja
Country [150] 0 0
Serbia
State/province [150] 0 0
Novi Sad
Country [151] 0 0
Slovakia
State/province [151] 0 0
Kosice
Country [152] 0 0
Slovakia
State/province [152] 0 0
Martin
Country [153] 0 0
Slovakia
State/province [153] 0 0
Puchov
Country [154] 0 0
Slovakia
State/province [154] 0 0
Rimavska Sobota
Country [155] 0 0
Slovenia
State/province [155] 0 0
Izo
Country [156] 0 0
Slovenia
State/province [156] 0 0
Ljubljana
Country [157] 0 0
Slovenia
State/province [157] 0 0
Maribor
Country [158] 0 0
Spain
State/province [158] 0 0
A Coruna
Country [159] 0 0
Spain
State/province [159] 0 0
Cordoba
Country [160] 0 0
Spain
State/province [160] 0 0
Madrid
Country [161] 0 0
Spain
State/province [161] 0 0
Malaga
Country [162] 0 0
Spain
State/province [162] 0 0
Murcia
Country [163] 0 0
Spain
State/province [163] 0 0
Móstoles
Country [164] 0 0
Spain
State/province [164] 0 0
Santiago de Compostela
Country [165] 0 0
Spain
State/province [165] 0 0
Sevilla
Country [166] 0 0
Taiwan
State/province [166] 0 0
Hsin Chu
Country [167] 0 0
Taiwan
State/province [167] 0 0
Kaohsiung
Country [168] 0 0
Taiwan
State/province [168] 0 0
Taichung
Country [169] 0 0
Taiwan
State/province [169] 0 0
Taipei
Country [170] 0 0
Taiwan
State/province [170] 0 0
Tao-Yuan
Country [171] 0 0
Taiwan
State/province [171] 0 0
Yung-Kang, Tainan
Country [172] 0 0
Turkey
State/province [172] 0 0
Istanbul
Country [173] 0 0
Turkey
State/province [173] 0 0
Kocaeli
Country [174] 0 0
Turkey
State/province [174] 0 0
Konya
Country [175] 0 0
Ukraine
State/province [175] 0 0
Cherkasy
Country [176] 0 0
Ukraine
State/province [176] 0 0
Kharkiv
Country [177] 0 0
Ukraine
State/province [177] 0 0
Khmelnitsky
Country [178] 0 0
Ukraine
State/province [178] 0 0
Kiev
Country [179] 0 0
Ukraine
State/province [179] 0 0
Kryvyi Rih
Country [180] 0 0
Ukraine
State/province [180] 0 0
Kyiv
Country [181] 0 0
Ukraine
State/province [181] 0 0
Odessa
Country [182] 0 0
Ukraine
State/province [182] 0 0
Poltava
Country [183] 0 0
Ukraine
State/province [183] 0 0
Sumy
Country [184] 0 0
Ukraine
State/province [184] 0 0
Ternopil
Country [185] 0 0
Ukraine
State/province [185] 0 0
Vinnytsia
Country [186] 0 0
Ukraine
State/province [186] 0 0
Vinnytsya
Country [187] 0 0
Ukraine
State/province [187] 0 0
Zhytomyr

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Janssen Research & Development, LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
Trial website
https://clinicaltrials.gov/study/NCT04882098
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Janssen Research & Development, LLC Clinical Trial
Address 0 0
Janssen Research & Development, LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Study Contact
Address 0 0
Country 0 0
Phone 0 0
844-434-4210
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04882098